Latest Harness Therapeutics News & Updates

See the latest news and media coverage for Harness Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Harness Therapeutics

Biotechnology company developing neurodegeneration therapies

harnesstx.com

Headquarters: Cambridge, United Kingdom
Founded year: 2023
Company type: Private company
Number of employees: 30–50

Last updated Today

Latest news about Harness Therapeutics

In short: Harness Therapeutics advanced its neurodegenerative pipeline by securing MJFF funding and nominating HRN001 as a lead candidate for Huntington’s.

Company announcements

June 16 Harness Therapeutics

Harness Therapeutics awarded grant from Michael J. Fox Foundation

The grant funds a two-year proof-of-concept study targeting GCase and LIMP2 upregulation via MISBA platform.

February 16 Harness Therapeutics

Harness Therapeutics nominates HRN001 for Huntington’s disease

HRN001 is a first-in-class antisense oligonucleotide upregulating FAN1. The company forms a Clinical Advisory Board to guide clinical progression in 2027.

February 1 Harness Therapeutics

Harness Therapeutics appoints Meenu Chhabra Karson as Board Chair

She brings over 20 years of biopharma experience, including fundraising, partnerships, and leadership roles at Samsara Therapeutics and others. Her expertise supports growth in neurodegenerative therapeutics.

6 October 2025 Harness Therapeutics

Harness Therapeutics announces MISBA Duo platform launch

The platform enables simultaneous upregulation and downregulation of two targets. It collaborates with Ono Venture Investment on an R&D program for a rare triplet repeat disorder.

Media coverage

February 16 Markets Insider

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington's Disease and Establishes Clinical Advisory Board

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated...

6 October 2025 GlobeNewswire

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment Proprietary MISBA Duo technology is...

19 February 2025 MENAFN

Harness Therapeutics Appoints Experienced R&D Executive And Physician-Scientist, Dr Paulo Fontoura, As Non-Executive Director

(MENAFN- GlobeNewsWire - Nasdaq) Dr Paulo Fontoura brings 20 years' experience of working in the pharma industry, with the most recent 16 years focusing on...

19 February 2024 Yahoo Finance

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases

Proceeds to be used to advance lead programme targeting FAN1 nuclease in Huntington's Disease towards the clinic Harness Therapeutics was originally established as Transine Therapeutics...

Never miss news about Harness Therapeutics

Track Harness Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Harness Therapeutics competitors & trending companies

Browse news for competitors to Harness Therapeutics and other trending companies.